Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 57 |
| Active Pipeline (Recruiting Now) | 39 (23) |
| Completed vs Stopped Early | 13 / 5 (8.8%) |
| Median Closed Actual Enrollment | 30 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Medical College of Wisconsin | Milwaukee, WI | 9 |
| Memorial Sloan Kettering Cancer Center | New York, NY | 4 |
| Children's Hospital of Wisconsin | Milwaukee, WI | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06517641 | Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia | Phase II | RECRUITING |
| NCT05032820 | Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Medical College of Wisconsin Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.